Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

The firm highlighted that Bristol-Myers Squibb Company (NYSE:BMY) will face loss of exclusivity challenges up to 2028, ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Best High Yield Stocks to Buy. On January 7, UBS upgraded ...

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Bristol-Myers Squibb Company is placed second among the ...

Share price of Bristol Myers Squibb (BMY) touched a 52-week low of $42.96 on July 31, post its second-quarter earnings release. The stock has recovered 6.7% since then and is currently trading at ...

Bristol Myers Squibb BMY highlighted the potential of its deep and promising pipeline at the 44th Annual J.P. Morgan ...

Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major’s shares have gained ...

At first glance, Bristol-Myers Squibb appears cheap with a low P/E and strong dividend yield. GAAP earnings are consistently much lower than non-GAAP figures, reflecting costs which may limit cash ...

Bristol Myers Squibb remains significantly undervalued, trading at a forward P/E of 8x, versus the sector median of 19.5x. BMY's growth portfolio now generates 57% of total revenue, growing 18% YoY ...